Comparative Study between The Efficacy and Safety of Topical Immune Therapy with Diphenylcyclopropenone versus Anthralin in The Treatment of Resistant Alopecia Areata

This study compared the efficacy and safety of topical diphenylcyclopropenone (DPCP) versus anthralin ointment in treating resistant alopecia areata in 30 subjects. The results showed that DPCP led to a significantly higher hair regrowth rate, with 60% of patients experiencing a very good response compared to 20% in the anthralin group. The absence of response was lower in the DPCP group (6.1%) compared to the anthralin group (26.7%). Although one patient in the DPCP group experienced a relapse, there were no significant differences in side effects between the two treatments. Overall, DPCP was found to be more effective than anthralin, with both treatments having a comparable safety profile.